Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10767042 | Biochemical and Biophysical Research Communications | 2007 | 7 Pages |
Abstract
Cell-based therapies are used to treat bone defects. We recently described that human multipotent adipose-derived stem (hMADS) cells, which exhibit a normal karyotype, self renewal, and the maintenance of their differentiation properties, are able to differentiate into different lineages. Herein, we show that hMADS cells can differentiate into osteocyte-like cells. In the presence of a low amount of serum and EGF, hMADS cells express specific molecular markers, among which alkaline phosphatase, CBFA-1, osteocalcin, DMP1, PHEX, and podoplanin and develop functional gap-junctions. When loaded on a hardening injectable bone substitute (HIBS) biomaterial and injected subcutaneously into nude mice, hMADS cells develop mineralized woven bone 4 weeks after implantation. Thus hMADS cells represent a valuable tool for pharmacological and biological studies of osteoblast differentiation in vitro and bone development in vivo.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Biochemistry
Authors
Christian Elabd, Chiara Chiellini, Ali Massoudi, Olivia Cochet, Laure-Emmanuelle Zaragosi, Christophe Trojani, Jean-François Michiels, Pierre Weiss, Georges Carle, Nathalie Rochet, Claude A. Dechesne, Gérard Ailhaud, Christian Dani, Ez-Zoubir Amri,